Dr. Reddy’s Laboratories Limited (NYSE:RDY) Stake Lifted by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC increased its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 348.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,729 shares of the company’s stock after acquiring an additional 13,001 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Dr. Reddy’s Laboratories were worth $264,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in RDY. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after acquiring an additional 137 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Dr. Reddy’s Laboratories by 64.3% during the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after buying an additional 322 shares in the last quarter. Assetmark Inc. boosted its holdings in Dr. Reddy’s Laboratories by 8.1% during the third quarter. Assetmark Inc. now owns 37,666 shares of the company’s stock worth $2,993,000 after buying an additional 2,836 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Dr. Reddy’s Laboratories during the third quarter worth approximately $60,000. Finally, OneDigital Investment Advisors LLC bought a new stake in Dr. Reddy’s Laboratories during the third quarter worth approximately $277,000. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Trading Up 0.0 %

Shares of NYSE:RDY opened at $12.71 on Wednesday. The stock has a market capitalization of $10.61 billion, a price-to-earnings ratio of 20.23 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.62 and a 1-year high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a 50 day moving average price of $14.12 and a 200 day moving average price of $14.90.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.